EP2001477A4 - Paclitaxel combination - Google Patents

Paclitaxel combination

Info

Publication number
EP2001477A4
EP2001477A4 EP07753541A EP07753541A EP2001477A4 EP 2001477 A4 EP2001477 A4 EP 2001477A4 EP 07753541 A EP07753541 A EP 07753541A EP 07753541 A EP07753541 A EP 07753541A EP 2001477 A4 EP2001477 A4 EP 2001477A4
Authority
EP
European Patent Office
Prior art keywords
paclitaxel combination
paclitaxel
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07753541A
Other languages
German (de)
French (fr)
Other versions
EP2001477A2 (en
Inventor
Ajay Bhargava
Christopher Carter
Michael Brands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of EP2001477A2 publication Critical patent/EP2001477A2/en
Publication of EP2001477A4 publication Critical patent/EP2001477A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP07753541A 2006-03-20 2007-03-20 Paclitaxel combination Withdrawn EP2001477A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78495406P 2006-03-20 2006-03-20
PCT/US2007/006920 WO2007109275A2 (en) 2006-03-20 2007-03-20 Paclitaxel combination

Publications (2)

Publication Number Publication Date
EP2001477A2 EP2001477A2 (en) 2008-12-17
EP2001477A4 true EP2001477A4 (en) 2010-07-21

Family

ID=38523056

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07753541A Withdrawn EP2001477A4 (en) 2006-03-20 2007-03-20 Paclitaxel combination

Country Status (4)

Country Link
EP (1) EP2001477A4 (en)
JP (1) JP2009530386A (en)
CA (1) CA2646971A1 (en)
WO (1) WO2007109275A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5081161B2 (en) 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション Farnesoid X receptor agonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050277640A1 (en) * 2003-10-10 2005-12-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
WO2006099231A1 (en) * 2005-03-10 2006-09-21 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4469179B2 (en) * 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Pyrimidine derivatives as Rho kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050277640A1 (en) * 2003-10-10 2005-12-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
WO2006099231A1 (en) * 2005-03-10 2006-09-21 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUNG CANCER DISEASE SITE GROUP OF CANCER CARE ONTARIO'S PROGRAM IN ET AL: "Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline", LUNG CANCER, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.LUNGCAN.2005.06.010, vol. 50, no. 3, 1 December 2005 (2005-12-01), pages 355 - 374, XP025286893, ISSN: 0169-5002, [retrieved on 20051201] *

Also Published As

Publication number Publication date
EP2001477A2 (en) 2008-12-17
WO2007109275A2 (en) 2007-09-27
WO2007109275A3 (en) 2009-04-02
CA2646971A1 (en) 2007-09-27
JP2009530386A (en) 2009-08-27

Similar Documents

Publication Publication Date Title
DE602007002700D1 (en) Interventionsfreies frac-system
EP2078282A4 (en) E-couponing
EP2033216A4 (en) Electroadhesion
DE602007008085D1 (en) Dihydropyrazolopyrimidinonderivate
DE602007014031D1 (en) Luftreifensatz
DE602007002070D1 (en) 2-pyrazincarboxamidderivate
DE602007003855D1 (en) Isothermer reaktor
EP1983992A4 (en) 2-imino-benzimidazoles
DE602007001601D1 (en) Glasuntersuchung
ZA200903041B (en) Combination
DE602007006989D1 (en) Spiropiperidinderivate
GB0609530D0 (en) Combination
GB0609619D0 (en) Combination
AP2008004724A0 (en) Substituted1-yl)-azolin-2-aryl-1-hetaryl-ethane
DE602007011622D1 (en) Penem-prodrugs
EP2084019A4 (en) Paintscraper
EP2024567A4 (en) Earthen-wallpaper
EP2007388A4 (en) Opiopathies
DK1989111T3 (en) Satellitluftbremseapparat
EP1974618A4 (en) Innerwear
EP2001477A4 (en) Paclitaxel combination
DE502007001126D1 (en) Eiten
AU4914P (en) CalflatGL Calothamnus quadrifidus
AU3514P (en) ARCBENT Arctotis fastuosa
GB0609531D0 (en) Combination

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20090402

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/337 20060101AFI20090420BHEP

17P Request for examination filed

Effective date: 20091002

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20100621

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20100615BHEP

Ipc: A61K 31/506 20060101ALI20100615BHEP

Ipc: A61K 9/00 20060101ALI20100615BHEP

Ipc: A61K 31/337 20060101AFI20090420BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101001